 Shares of Gamida Cell NASDAQ:GMDA moved higher by 1.6 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 15.91 over the past year to 0.37, which missed the estimate of 0.30.Revenue of 0 unchanged by 0.00 from the same period last year, which missed the estimate of 140,000.Looking Ahead Gamida Cell hasnt issued any earnings guidance for the time being.Revenue guidance hasnt been issued by the company for now.Conference Call Details Date: Aug 11, 2020View more earnings on GMDATime: 08:30 AMET Webcast URL: Action 52-week high: 7.7052-week low: 2.60Price action over last quarter: down 16.98Company Description Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. The companys product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant. It is also developing GDA-201 which is innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. It is developing a diverse pipeline of cell therapies using its proprietary NAM technology that has the potential to bring life-saving treatment options to patients.See more from Benzinga Earnings Scheduled For August 11, 2020C 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 